1. Clinical Overview
Piperacillin and Tazobactam is a fixed-dose, injectable combination of a broad-spectrum penicillin antibiotic (piperacillin) and a beta-lactamase inhibitor (tazobactam). Piperacillin is an extended-spectrum penicillin with activity against a wide range of Gram-positive and Gram-negative bacteria, including Pseudomonas aeruginosa. Tazobactam irreversibly inhibits many beta-lactamase enzymes, protecting piperacillin from degradation and extending its spectrum to include many beta-lactamase-producing strains. This combination is a cornerstone of empiric therapy for serious hospital-acquired infections in the Indian setting.
| Onset | Duration | Bioavailability |
|---|---|---|
| Rapid, with peak plasma concentrations achieved within 30 minutes after a 30-minute intravenous infusion. | The dosing interval is typically every 6 to 8 hours, guided by the half-life and the principle of time-dependent bacterial killing. | Not applicable (Intravenous administration only). |
2. Mechanism of Action
Piperacillin binds to penicillin-binding proteins (PBPs) located inside the bacterial cell wall, inhibiting the final transpeptidation step of peptidoglycan synthesis. This leads to the formation of defective cell walls and osmotically unstable cells, causing cell lysis and death (bactericidal). Tazobactam has weak antibacterial activity but is a potent, irreversible inhibitor of many plasmid- and chromosomally-encoded beta-lactamases, including TEM, SHV, and some OXA enzymes. It protects piperacillin from enzymatic hydrolysis, thereby restoring and extending its antibacterial spectrum.
3. Indications & Uses
- Intra-abdominal infections (complicated)
- Nosocomial pneumonia (including ventilator-associated pneumonia)
- Septicemia
- Febrile neutropenia (empiric therapy)
- Skin and skin structure infections (complicated)
- Pelvic inflammatory disease
- Urinary tract infections (complicated)
4. Dosage & Administration
Adult Dosage: 3.375 g (piperacillin 3g + tazobactam 0.375g) IV every 6 hours OR 4.5 g (piperacillin 4g + tazobactam 0.5g) IV every 8 hours for serious infections. For nosocomial pneumonia, febrile neutropenia, and complicated intra-abdominal infections: 4.5 g every 6 hours.
Administration: For IV infusion only. Reconstitute powder with a suitable diluent (e.g., 0.9% Sodium Chloride, 5% Dextrose). Further dilute to a final volume of 50-150 mL. Infuse over 30 minutes. Do not mix with aminoglycosides in the same IV line/bag due to physical incompatibility. Administer separately.
5. Side Effects
Common side effects may include:
- Diarrhea (including Clostridioides difficile-associated diarrhea)
- Headache
- Insomnia
- Nausea/Vomiting
- Constipation
- Rash/Pruritus
- Local reactions at injection site (phlebitis, pain)
6. Drug Interactions
| Drug | Effect | Severity |
|---|---|---|
| Probenecid | Inhibits renal tubular secretion of piperacillin, increasing and prolonging serum concentrations of both drugs. | Moderate |
| Aminoglycosides (Gentamicin, Amikacin) | Physical incompatibility when mixed in same IV line. In vitro antagonism has been reported for some strains. Clinical significance is uncertain. Monitor renal function. | Moderate |
| Methotrexate | Piperacillin may reduce renal clearance of methotrexate, leading to increased and prolonged serum methotrexate levels and risk of toxicity. | Major |
| Oral Anticoagulants (Warfarin) | May potentiate anticoagulant effect, increasing risk of bleeding. Monitor INR closely. | Major |
| Vecuronium | May prolong neuromuscular blockade. | Moderate |
| Live Bacterial Vaccines (e.g., Typhoid, BCG) | Antibiotics may diminish the therapeutic effect of live bacterial vaccines. | Moderate |
7. Patient Counselling
- Do inform your doctor about any history of allergies, especially to penicillin or other antibiotics.
- Do complete the full course of treatment even if you feel better.
- Do inform your doctor if you are pregnant, planning pregnancy, or breastfeeding.
- Do report any severe diarrhea (watery or bloody) during or after treatment.
- Do not skip doses.
- Do not mix this medicine with any other medication in the same IV line unless instructed.
8. Toxicology & Storage
Overdose: Neurological manifestations including convulsions, encephalopathy, neuromuscular excitability, or seizures. Electrolyte imbalances (hypernatremia, hypokalemia). Exacerbation of other adverse effects like nausea, vomiting, diarrhea.
Storage: Store unopened vials/powder at or below 25°C, protected from light and moisture. Keep out of reach of children. After reconstitution and dilution: Chemical and physical stability of the diluted solution has been demonstrated for up to 24 hours at room temperature (25°C) or up to 7 days when refrigerated (2-8°C) in compatible diluents. Do not freeze. Discard any unused solution after the recommended time.